Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: A subanalysis from the RATIFY trial
    Journal Article

    Voso, M. T.; Larson, R. A.; Jones, D.; Marcucci, G.; Prior, T.; Krauter, J.; Heuser, M.; Lavorgna, S.; Nomdedeu, J.; Geyer, S. M.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Combined JAK2 and ERK1/2 kinase inhibition as a novel therapeutic approach in myeloproliferative neoplasms
    Meeting Abstract

    Brkic, S.; Stivala, S.; Santopolo, A.; Jungius, S.; Passweg, J. R.; Tsakiris, D.; Dirnhofer, S.; Levine, R. L.; Meyer, S. C.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Resistance to type II JAK2 inhibition in MPN is dependent on MEK-ERK activation and is targetable
    Meeting Abstract

    Codilupi, T.; Szybinski, J.; Wicki, A.; Yang, J. L.; Ghosh, N.; Passweg, J.; Tsakiris, D.; Levine, R. L.; Koche, R.; Meyer, S. C.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Dual genetic targeting of ERK1 and ERK2 abrogates the competitive potential of the myeloproliferative neoplasm clone
    Meeting Abstract

    Stivala, S.; Brkic, S.; Santopolo, A.; Dirnhofer, S.; Passweg, J.; Tsakiris, D.; Neel, B.; Levine, R.; Meyer, S.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Carter, J.; Dogan, A.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; Abramson, J. S.; Batlevi, C. L.; Joffe, E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study
    Meeting Abstract

    Sharman, J. P.; Brander, D. M.; Mato, A. R.; Ghosh, N.; Schuster, S. J.; Kambhampati, S.; Burke, J. M.; Lansigan, F.; Schreeder, M. T.; Lunin, S. D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Long-term survivors and gilteritinib safety beyond one year in FLT3-mutated R/R AML: ADMIRAL trial follow-up
    Meeting Abstract

    Perl, A. E.; Martinelli, G.; Neubauer, A.; Berman, E.; Baer, M. R.; Larson, R. A.; Fathi, A. T.; Yokoyama, H.; Hosono, N.; Hasabou, N.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Effects of radiation therapy on clonal hematopoiesis
    Meeting Abstract

    Modlin, L. A.; Wijetunga, N. A.; Patel, M.; Gao, T.; Ptashkin, R.; Sullivan, M. R.; Kelly, D. W.; Caltabellotta, N.; Solit, D. B.; Berger, M. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results
    Meeting Abstract

    Mato, A. R.; Sharman, J. P.; Biondo, J.; Wu, M.; Mun, Y.; Kim, S. Y.; Humphrey, K.; Boyer, M.; Zhu, Q.; Seymour, J. F.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia
    Meeting Abstract

    Januzzi, J. L.; Garasic, J.; Kasner, S.; McDonald, V.; Petrie, M. C.; Seltzer, J.; Mauro, M. J.; Croce, K.; Berman, E.; Deininger, M. W. N.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save